Delivering next generation cell therapies
Metastatic solid cancers largely remains incurable despite advances in immunotherapy
Despite the promise of immunotherapy, metastatic solid tumours largely remain untreatable. Current approaches face significant limitations, including toxicity, inefficacy in solid tumours, and reliance on pre-existing immune responses. There is an urgent need for a broadly applicable therapy that generates a powerful, sustained cellular immune attack on advanced solid cancers.
>9 million
annual deaths from solid tumours worldwide (estimated)
Mani, K. et al. Causes of death among people living with metastatic cancer. Nat Com 15, 1519 (2024). https://doi.org/10.1038/s41467-024-45307-x
>82.4%
of patients with metastatic cancer will die from their disease
Cancer TODAY | IARC Age-Standardized Rate (World) per 100 000, Mortality, Both sexes, in 2022, World, https://gco.iarc.who.int
The ideal T cell therapeutic platform targeting solid tumours
Immune System Priming
Vaccine primes immune system including new tumour-Ag specific T cells but quickly reaches equilibrium
Swarm T Cell isolation
Our unique process discards non-effective immune cells and enriches the fittest Ag-specific T cells
Product Manufacturing
Swarm manufactures potent, early memory T cells from peripheral blood
Immune System Reactivation
We return a high dose of Ag-specific and highly optimized T cells as a therapeutic treatment.
Targeted & potent approach to the treatment in solid tumours
In vivo priming
Selecting a tumour specific t cell response already primed for therapeutic effect
Effective screening
Our platform incorporates rigorous screening to ensure the selection of patients that could benefit and to optimise manufacturability.
Isolating the correct cells
Selecting tumour targeting t cells from the patient as a starting cell population.
Expanding fitter and durable T cells
We expand T cells to therapeutic doses while preserving their vitality, potency, and long-term persistence in the patient’s body.
Pipeline
Collaborate to advance the science
Our platform is built to deliver powerful, personalised T cell therapies-but partnerships make it possible. From co-development to strategic investment, we welcome opportunities to accelerate innovation and patient impact.
